Post by AESARA

The US Most-Favored-Nation policy is the most consequential shift in global pharmaceutical pricing in a generation. Pricing decisions made in Europe now directly affect US revenue. The mechanics—and the strategic options—were the focus of yesterday's invite-only workshop in Cambridge, MA, co-hosted by AESARA and a multinational expert network spanning the UK, France, Germany, and Scandinavia. Lung-I Cheng, VP of Global Value & Access at AESARA, opened with a framing question: how do you launch in Europe while protecting your US price under MFN? The room—pharma and biotech leaders working through #MFN exposure in real time—was direct about where things stand. When polled on whether current MFN policies will achieve the administration's goal of rebalancing global drug prices, roughly two-thirds disagreed. Most of the skepticism was hedged—"somewhat disagree" rather than "strongly disagree." Skeptical, but watching closely. That tracks with what we're hearing from clients. The policy is in motion. The mechanics—GENEROUS, GLOBE, GUARD—are still resolving. The strategic options for protecting US price while still launching in reference markets are real but narrow, and they require coordinated decisions across pricing, evidence generation, and launch sequencing. Thank you to the multinational expert network—Zealth, Ecker + Ecker GmbH, CEMKA (France), and Cogentia Healthcare Consulting—for an afternoon that was as substantive as the topic deserves. If your team is working through MFN planning: this is the conversation. Reach out to Lung-I directly, or find us at upcoming sessions. #MFN #MarketAccess #Pharmaceuticals #HEOR #DrugPricing #AESARA10